

## **PRESS RELEASE**

### **NANOBIOTIX ANNOUNCES TEMPORARY TRADING HALT OF ITS ORDINARY SHARES ON Euronext PARIS**

**PARIS and CAMBRIDGE, Mass., May 21, 2026** – NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “**Nanobiotix**” or the “**Company**”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris (“**Euronext Paris**”) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“**ADSs**”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “**Ordinary Share**”), of the Company, in the United States (the “**U.S. Offering**”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “**International Offering**” and, together with the U.S. Offering, the “**Global Offering**”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.

This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume on May 21, 2026, at approximately at approximately 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).

### **About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States), amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

## Contacts

*Nanobiotix*

### **Communications Department**

*Brandon Owens*  
*VP, Communications*  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

### **Investor Relations Department**

*Joanne Choi*  
*VP, Investor Relations (US)*  
+1 (713) 609-3150

*Ricky Bhajun*  
*Director, Investor Relations (EU)*

[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

### *Media Relations*

France – **HARDY**  
*Caroline Hardy*  
+ 33 06 70 33 49 50  
[carolinehardy@outlook.fr](mailto:carolinehardy@outlook.fr)

Global – **uncapped Communications**  
*Becky Lauer*  
+1 (646) 286-0057  
[uncappednanobiotix@uncappedcommunications.com](mailto:uncappednanobiotix@uncappedcommunications.com)

## Disclaimers

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.